Welcome to Discovery Analytical Consulting

Based in Cambridge, UK at the heart of Europe's largest life science and healthcare cluster, we offer a unique set of consulting services, in-sourced support and software solutions aligned to current models of networked R&D.

With over 30 years of experience working for and with Pharma and Biotech companies globally, we have a deep insight into different companies' practices, technologies and cultures and we are able to share this knowledge and experience with our customers adding significant value to the consulting services that we provide in Analytical Chemistry, Purification and Compound Management to enhance your infrastructure and operational management. This can be provided via a short term consultancy agreement or under a cost-effective, longer term in-house working arrangement.

Workflow support for Scientists working in screening, ADME/DMPK and Pharmacology is provided in association with The Edge software consultancy and delivers innovative solutions for massively improved research productivity. We also support Research informatics solutions from Collaborative Drug Discovery, Inc.

We work with ChemPharmaServe to act as an outsourcing gateway to a diverse range of research, development and manufacturing services including the provision of materials you need to facilitate your research and development plans. Our collaboration with Bio-Mimetic Chromatography Ltd supports compound optimisation via biomimetic property measurements by HPLC. Our network of partners includes Abundnz N.V. who bring expertise in bioanalysis of large molecule drugs and their sister company Immundnz who are focussed on immunogenicity testing while EM Analytical provide powerful microscopy technology that adds a new dimension to drug discovery, e.g. through direct observation of target engagement. We also work in partnership with MIP Diagnostics Ltd to promote and support their revolutionary technology in the field of Molecularly Imprinted Polymers (MIPs). 


Extensive experience

We have extensive experience in building high performing Analytical Teams from scratch, including development of the necessary infrastructure, technical training and on-going management of these teams to deliver key products and services essential to the successful execution of projects.

Learn More →

Areas of Expertise

We have applied our expertise in Separation Science to many aspects of Drug Discovery including supporting key functions such as Medicinal Chemistry, physico-chemical measurement, ADME screening, Bioanalysis and Compound Management.

Learn More →

What we offer


About Mark

Mark has worked for a variety of Leading Global Pharmaceutical Research Companies including AstraZeneca (UK), Galapagos NV (Belgium) and Takeda (UK).  

In addition, in 2000 he co-founded CombiPure, a CRO focussed on Combinatorial Chemistry services.

Mark also has significant people management and leadership experience at senior levels which ensures rapid understanding and alignment with your corporate goals and priorities for the lab functions supported. He is a Fellow of the Royal Society of Chemistry (FRSC) and a committee member for the UK Chromatographic Society.


Discovery Analytical Consulting - Mark Portsmouth - Director.jpg
Discovery Analytical Consulting - Galapagos.jpg
Discovery Analytical Consulting - Takeda.jpg
Discovery Analytical Consulting - CombiPure.jpg

Referrals and Testimonials

Discovery Analytical Consulting - Peter Ridgway - Testimonial.jpg

“I have been interacting with Mark for over 9 years. It has always been a client / vendor relationship during his time with Takeda.

What strikes you very quickly with Mark is that you are dealing with a very talented scientist.
His knowledge and abilities in the fields of analytical science, chromatography and mass spec are very much in the upper echelons of the client base I have interacted with in the last 9 years.

Every aspect of supporting drug discovery is covered in Mark’s abilities. He provides a very comprehensive solution.  
Another element of Mark’s professional approach is his willingness to embrace new or cutting edge technology. On numerous occasions we have discussed his plans to utilise new technology to make his areas of his responsibility deliver more efficiently. He is not set in his ways and strives to improve performance and productivity. His openness to work differently is very clear.

It is therefore a very simple task to recommend Mark. I am in no doubt that he would add significant value to any drug discovery type organization.”

 - Peter Ridgway, Director at Reach Separations, Nottingham, UK